Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 758 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Topical Diclofenac Gel Reduces the Incidence of Hand-Foot Syndrome in Patients... March 6, 2024 EMA Adopts a Positive Opinion for Dabrafenib for the Treatment of... September 25, 2023 Woman Who Died For 27 Minutes Shares Haunting Message When Revived August 12, 2019 When Caregiving Takes a Toll May 28, 2021 Load more HOT NEWS Will Ponsegromab Be a Game Changer for Cancer Cachexia? Veteran Drops To The Ground When He Hears How Much His... Adding Gemcitabine to Cisplatin Once per Week Concurrently with IMRT Significantly... A New FDA Approval Furthers the Role of Genomics in Cancer...